Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | CTLA-4 |
Clinical data | |
Pronunciation | i pi lim′ ue mab |
Trade names | Yervoy |
Other names | BMS-734016,[1] MDX-010,[2] MDX-101 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611023 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous (IV) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C6742H9972N1732O2004S40 |
Molar mass | 148634.46 g·mol−1 |
(what is this?) (verify) |
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Cytotoxic T lymphocytes (CTLs) can recognize and destroy cancer cells. However, an inhibitory mechanism interrupts this destruction.[6] Ipilimumab turns off this inhibitory mechanism and boosts the body's immune response against cancer cells.[6][7]
Ipilimumab was approved by the US Food and Drug Administration (FDA) in March 2011, for the treatment of melanoma, renal cell carcinoma (RCC), colorectal cancer, hepatocellular carcinoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, esophageal cancer.[8][9][10][11] It is undergoing[when?] clinical trials for the treatment of bladder cancer[12] and metastatic hormone-refractory prostate cancer.[13]
The concept of using anti-CTLA4 antibodies to treat cancer was first developed by James P. Allison while he was director of the Cancer Research Laboratory at the University of California, Berkeley.[14][15] Clinical development of anti-CTLA4 was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. For his work in developing ipilimumab, Allison was awarded the Lasker Award in 2015.[16] Allison later was the co-winner of the 2018 Nobel Prize in Physiology or Medicine.[17]
Ribas
was invoked but never defined (see the help page).